Effect of duloxetine and pregabalin on invalidation in fibromyalgia.

Phase 3

Recruiting

• Conditions: Invalidation in patient with fibromyalgia.; Fibromyalgia; M79.7

• Registration Number: IRCT20181113041646N1
• Lead Sponsor: Rasht University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 17 December 2019

Recruitment & Eligibility

• Status: Recruiting
• Sex: Female
• Target Recruitment: 68

Inclusion Criteria

Female .
Patients must meet the American College of Rheumatology criteria for fibromyalgia (ACR2010).
A rheumatologist confirm diagnosis of fibromyalgia.

Exclusion Criteria

Age younger than 18 or older than 65 years old
Pregnancy .
Taking MAOIs (monoamine oxidase inhibitors) in the 14 days before study.
Cases of chronic liver disease, severe renal failure and uncontrolled narrow angle glaucoma.
History of sensitivity to Pregabalin and its components.
History of sensitivity to Duloxetine and its components.

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Invalidation in patient with fibromyalgia. Timepoint: Before starting the study, then one month after taking medication. Method of measurement: Illness invalidation questionnaire.;Depression score in Beck depression inventory. Timepoint: Before starting the study,then one month after taking medication. Method of measurement: Beck depression questionnaire.

Secondary Outcome Measures

Name	Time	Method
Severity of disease. Timepoint: Before starting the study, then one month after taking medication. Method of measurement: FIQR Questionnaire.